Non-Interventional Study of Tocilizumab Subcutaneous (SC) Monotherapy in Participants With Rheumatoid Arthritis (RA)

  • Autoimmune Disorder
  • Rheumatoid Arthritis
Please note that the recruitment status of the study at your site may differ from the overall study status because some study sites may recruit earlier than others.
Study Status:

Completed

This study runs in
Cities
  • Budapest
  • Debrecen
  • Eger
  • Esztergom
  • Gyula
  • Győr
  • Heviz
  • Kecskemét
  • Kistarcsa
  • Miskolc
  • Nyíregyháza
  • Pécs
  • Szeged
  • Szombathely
  • Székesfehérvár
  • Veszprém
Trial Identifier:

NCT02402686 ML29719

      Show study locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical study see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Study Summary

      The aim of this non-interventional study in Hungarian participants is to gather real life data about the efficacy and safety of tocilizumab SC monotherapy in RA, to assess data about pattern of usage of tocilizumab monotherapy in RA disease management.

      Hoffmann-La Roche Sponsor
      N/A Phase
      NCT02402686, ML29719 Trial Identifier
      Tocilizumab Treatments
      Rheumatoid Arthritis Condition
      Official Title

      Open-Label, Multi-Center, Non-Interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab SC Monotherapy in Daily Clinical Practice (SIMPACT)

      Eligibility Criteria

      All Gender
      ≥ 18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Moderate to severe RA according to 2010 American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) joint criteria
      • Treatment with tocilizumab SC monotherapy for up to 8 weeks prior to enrollment, under the prescriptive authority of a physician who has made the decision to commence tocilizumab in accordance with the local label
      • Methotrexate intolerance, or inadequate response to prior DMARDs and TNF inhibitors where continued methotrexate treatment was deemed inappropriate
      Exclusion Criteria
      • Treatment with tocilizumab more than 8 weeks prior to enrollment
      • Failure to meet local tocilizumab label indication criteria
      • Treatment with any investigational agent within 4 weeks of beginning tocilizumab SC monotherapy
      • Last methotrexate dose within 1 week of beginning tocilizumab SC monotherapy
      • History of any other autoimmune or joint inflammatory disease

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Studies

      Use our search to find other trials on Genentech Clinical Trials in related disease areas.

      Rheumatoid Arthritis

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now